# paste in current grants from M-CV with datapasta = paste as vector
# update last paste date here: 7-apr-2021

current <- c("Grant#\tTitle\tSponsor Name\tRole in Grant\tTotal Direct/Indirect\tBegin Dt\tEnd Dt", "5 T32 DK062708-20\tTraining Program in Gastrointestinal Epidemiology", "[Updt By: phiggins]", "NIH-DHHS-US\tPI\t$851,851\t07/18\t06/23\tEdit\tDelete", "5 R01 DK118154-05\tInhibiting Bcl-2-regulated intestinal fibrosis in models of Crohn¿s Disease", "[Updt By: phiggins]", "NIH-DHHS-US\tPI\t$2,336,700\t07/18\t05/23\tEdit\tDelete", "Characterization of intestinal fibrosis and inflammation in Crohn's Disease by non-invasive photoacoustic imaging", "[Updt By: phiggins]", "Crohn's and Colitis Foundation\tCo-I with Effort\t$347,394\t07/18\t06/21\tEdit\tDelete", "Clinical Study Rider to TARGET-IBD Protocol under Master Agreement\tA 5-year Longitudinal Observational Study of Patients Undergoing IBD Therapy", "[Updt By: phiggins]", "Target PharmaSolutions, Inc\tPI\t$686,958\t05/18\t03/23\tEdit\tDelete", "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433", "[Updt By: phiggins]", "AbbVie, Inc.\tPI\t$1,204,550\t01/18\t11/22\tEdit\tDelete", "Sponsored Clinical Trial Agreement for Protocol SHP647-304\tA Phase 3 Long-term Safety Extension Study of SHP647 in Subjects with Moderate to Severe Ulcerative Colitis (AIDA)", "[Updt By: phiggins]", "Shire Human Genetic Therapies\tPI\t$173,993\t11/17\t11/21\tEdit\tDelete", "A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991", "[Updt By: phiggins]", "AbbVie, Inc.\tPI\t$962,980\t10/17\t08/24\tEdit\tDelete", "5 P30 DK034933-35\tUniversity of Michigan Center for Gastrointestinal Research", "[Updt By: phiggins]", "NIH-DHHS-US\tCo-I with Effort\t$3,328,114\t08/17\t05/22\tEdit\tDelete", "A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis (UC)", "[Updt By: phiggins]", "AbbVie, Inc.\tPI\t$36,147\t05/17\t05/23\tEdit\tDelete", "A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis (UC)", "[Updt By: phiggins]", "AbbVie, Inc.\tPI\t$374,999\t05/17\t05/23\tEdit\tDelete", "Statement of Work for GA29145 under Master Clinical Research Agreement\tAn Open-Label Extension and Safety Monitoring Study of Patients with Moderately to Severely Active Crohn¿s disease Previously Enrolled in the Etrolizumab Phase III protocol GA29144", "[Updt By: phiggins]", "Genentech, Inc. through a consortium with Quintiles, Inc\tPI\t$10,040\t06/16\t05/21\tEdit\tDelete", "Entyvio (vedolizumab) long-term safety study", "[Updt By: phiggins]", "Takeda Pharmaceuticals USA through a consortium with Mapi Research Institute\tPI\t$434,450\t02/16\t02/24\tEdit\tDelete", "Statement of Work for GA29145 under Master Clinical Research Agreement\tAn Open-Label Extension and Safety Monitoring Study of Patients with Moderately to Severely Active Crohn's disease Previously Enrolled in the Etrolizumab Phase III protocol GA29144", "[Updt By: phiggins]", "Hoffmann-Laroche, Inc through a consortium with Quintiles, Inc\tPI\t$304,440\t06/15\t05/21\tEdit\tDelete", "Statement of Work for GA28951 under Master Clinical Trial Agreement\tAn Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase II/III Studies", "[Updt By: phiggins]", "Genentech, Inc. through a consortium with Quintiles, Inc\tPI\t$20,919\t10/14\t10/21\tEdit\tDelete", "Statement of Work for GA28951 under Master Clinical Trial Agreement\tAn Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase III Studies", "[Updt By: phiggins]", "Genentech, Inc. through a consortium with Quintiles, Inc\tPI\t$355,842\t10/14\t10/21\tEdit\tDelete", "REGISTRY PROTOCOL P11-282 A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC)", "[Updt By: phiggins]", "AbbVie, Inc. through a consortium with Registrat\tPI\t$336,577\t08/14\t07/24\tEdit\tDelete", "SOW Protocol GA29145\tAn Open-Label Extension and Safety Monitoring Study of Patients with Moderately to Severely Active Crohn's disease Previously Enrolled in the Etrolizumab Phase III protocol GA29144", "[Updt By: phiggins]", "Genentech, Inc. through a consortium with Quintiles, Inc\tPI\t$6,615\t06/14\t05/21\tEdit\tDelete", "REGISTRY PROTOCOL P11-282 A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC)", "[Updt By: phiggins]", "AbbVie, Inc. through a consortium with Registrat\tPI\t$289,566\t08/13\t07/24\tEdit\tDelete", "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis", "[Updt By: phiggins]", "AbbVie, Inc.\tPI\t$0\t\t03/23\tEdit\tDelete", "A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 3", "[Updt By: phiggins]", "Eli Lilly and Company\tPI\t$0\t\t03/22\tEdit\tDelete", "A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects with Moderate to Severe Crohn¿s Disease (CARMEN CD 307)", "[Updt By: phiggins]", "Shire Human Genetic Therapies\tPI\t$0\t\t08/21\tEdit\tDelete", "An Open-Label Extension and Safety Monitoring Study of Patients with Moderately to Severely Active Crohn¿s disease Previously Enrolled in the Etrolizumab Phase III protocol GA29144", "[Updt By: phiggins]", "Genentech, Inc. through a consortium with Quintiles, Inc\tPI\t$0\t\t05/21\tEdit\tDelete", "A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease Who Have Failed Anti-TNF therapy", "[Updt By: Grants Load]", "AbbVie, Inc.\tPI\t$250,742\t03/21\t02/24\tEdit\tDelete", "Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD)", "[Updt By: Grants Load]", "Crohn's and Colitis Foundation\tCo-I without Effort\t$1,120,255\t10/20\t10/21\tEdit\tDelete", "5 K08 DK123403-05\tCD4+ Tissue resident memory T-cells in Crohn’s Disease", "[Updt By: Grants Load]", "NIH-DHHS-US\tCo-I without Effort\t$847,606\t09/20\t07/25\tEdit\tDelete", "A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065", "[Updt By: Grants Load]", "AbbVie, Inc.\tPI\t$384,929\t04/20\t03/23\tEdit\tDelete", "A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy", "[Updt By: Grants Load]", "AbbVie, Inc.\tPI\t$668,255\t04/20\t04/22\tEdit\tDelete", "Clinical Trial Agreement for Protocol SERES-201\tECO-RESET: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to-Moderate Ulcerative Colitis", "[Updt By: Grants Load]", "Seres Therapeutics\tPI\t$0\t07/19\t07/23\tEdit\tDelete", "A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects with Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)", "[Updt By: Grants Load]", "Shire Human Genetic Therapies\tPI\t$0\t11/17\t11/21\tEdit\tDelete", "A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991", "[Updt By: Grants Load]", "AbbVie, Inc.\tPI\t$0\t\t08/24\tEdit\tDelete", "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433", "[Updt By: Grants Load]", "AbbVie, Inc.\tPI\t$0\t\t11/22\tEdit\tDelete")

current %>% 
  str_replace_all(pattern = "\tEdit\tDelete", "") %>% 
  read_tsv() %>% 
  janitor::clean_names() %>% 
  filter(grant_number != "[Updt By: phiggins]") %>% 
  filter(grant_number != "[Updt By: Grants Load]") %>%   
  mutate(sponsor_name = case_when(is.na(sponsor_name) ~ lead(grant_number), TRUE ~ sponsor_name)) %>% 
  mutate(role_in_grant = case_when(is.na(role_in_grant) ~ lead(title), TRUE ~ role_in_grant)) %>% 
  mutate(total_direct_indirect = case_when(is.na(total_direct_indirect) ~ lead(sponsor_name), TRUE ~ total_direct_indirect)) %>% 
  mutate(begin_dt = case_when(is.na(begin_dt) & str_detect(string = total_direct_indirect, pattern = "$") ~ lead(role_in_grant), TRUE ~ begin_dt)) %>% 
  mutate(end_dt = case_when(is.na(end_dt) & str_detect(total_direct_indirect, "$") ~ lead(total_direct_indirect), TRUE ~ end_dt)) %>% 
  mutate(title = case_when(is.na(title) ~ grant_number, TRUE ~ title)) %>% 
  mutate(grant_number = case_when(title == grant_number ~ "", TRUE ~ grant_number)) %>% 
  filter(str_detect(end_dt, "/")) ->
current_grants

